Evolving concepts in Phase I and II Drug Development for Crohn's Disease.

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.

The highest attrition rates during drug development programs occur at the proof of concept stage. Given the large number of molecules under development for Crohn's disease, a need exists to improve the efficiency of early drug development by fast-tracking promising agents and terminating ineffe...

Bibliografski detalji
Glavni autori:	Jairath, V, Levesque, B, Vande Casteele, N, Khanna, R, Mosli, M, Hindryckx, P, Travis, S, Duijvenstein, M, Rimola, J, Panes, J, D'Haens, G, Sandborn, W, Feagan, B
Format:	Journal article
Jezik:	English
Izdano:	Oxford University Press 2016

Slični predmeti

Evolving concepts in phases I and II drug development for Crohn's Disease
od: Jairath, V, i dr.
Izdano: (2016)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
od: Sandborn, W, i dr.
Izdano: (2016)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
od: Jairath, V, i dr.
Izdano: (2016)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
od: D'Haens, G, i dr.
Izdano: (2009)

Biosimilars in IBD: hope or expectation?
od: Gecse, K, i dr.
Izdano: (2013)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
od: Peyrin-Biroulet, L, i dr.
Izdano: (2012)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
od: Danese, S, i dr.
Izdano: (2015)

Development of the Crohn's disease digestive damage score, the Lemann score.
od: Pariente, B, i dr.
Izdano: (2011)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
od: Khanna, R, i dr.
Izdano: (2023)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
od: Reinisch, W, i dr.
Izdano: (2018)

Central Endoscopy Reading in Inflammatory Bowel Diseases
od: Panés, J, i dr.
Izdano: (2016)

Systematic review and meta-analysis: Prevalence, risk factors, and costs of aminosalicylate use in Crohn’s disease
od: Ma, C, i dr.
Izdano: (2018)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
od: Gasche, C, i dr.
Izdano: (2000)

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
od: Samaan, MA, i dr.
Izdano: (2018)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
od: Van Assche, G, i dr.
Izdano: (2011)

Placebo response and remission rates in Ulcerative Colitis clinical trials: Systematic review and meta-analysis
od: Jairath, V, i dr.
Izdano: (2015)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis
od: Jairath, V, i dr.
Izdano: (2017)

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
od: Travis, S, i dr.
Izdano: (2006)

“Dramatische taalvaardigheid” and how to remediate it - Developing and evaluating a remedial writing programme in a Dutch-medium secondary school
od: D'Haens, A
Izdano: (2020)

Evolving concepts in sedimentology/
od: 461622 Ginsburg, Robert N.
Izdano: (1973)

The evolving concept of quality/
od: 411748 Hill-Scott, Karen, i dr.
Izdano: (1978)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
od: D'Haens, G, i dr.
Izdano: (2011)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
od: Panaccione, R, i dr.
Izdano: (2019)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
od: Colombel, J, i dr.
Izdano: (2017)

Crohn’s disease or Crohn’s diseases?
od: Arnott, IDR, i dr.
Izdano: (2003)

Medical management of Crohn's disease.
od: Cummings, JR, i dr.
Izdano: (2008)

Mortality in patients hospitalised with Crohn's disease.
od: Siffledeen, J, i dr.
Izdano: (2012)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
od: Mahadevan, U, i dr.
Izdano: (2011)

P313 Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study
od: Loftus, E, i dr.
Izdano: (2019)

Interfering with leukocyte trafficking in Crohn's disease
od: Biswas, S, i dr.
Izdano: (2019)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
od: D'Haens, G, i dr.
Izdano: (2018)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
od: Gottlieb, K, i dr.
Izdano: (2015)

Is Crohn's disease a rightly used eponym?
od: Van Hootegem, P, i dr.
Izdano: (2019)

Smoking status in therapeutic trials in Crohn's disease.
od: McGovern, D, i dr.
Izdano: (2005)

Evolving concepts of specificity in immune reactions
od: Chakraborty, Arup K, i dr.
Izdano: (2017)

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis.
od: Van Assche, G, i dr.
Izdano: (2010)

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
od: Sandborn, W, i dr.
Izdano: (2015)

Perianal Crohn's disease.
od: Singh, B, i dr.
Izdano: (2004)

Review article: insurance risks for patients with ulcerative colitis or Crohn's disease.
od: Travis, S
Izdano: (1997)

Influence of risk factors on the safety of ileocolic anastomosis in Crohn's disease surgery.
od: Tzivanakis, A, i dr.
Izdano: (2012)